Clinical Trial Update: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an individualized regimen of ranibizumab for choroidal neovascularization caused by pathological myopia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Choroidal Neovascularisation | Phase 2 | Status: COMPLETED